| 35 | 0 | 142 |
| 下载次数 | 被引频次 | 阅读次数 |
补体系统在维持免疫稳态中发挥关键作用,其异常激活与多种罕见病及常见疾病密切相关。近年来,靶向补体级联反应的生物药物迅速发展,已成为免疫治疗领域的重要研究方向。靶向补体治疗正从广谱阻断走向精准干预,显著改善了多种补体介导疾病的临床结局,但如何在扩大适应证的同时有效控制感染风险与个体化疗效差异,仍是当前转化医学面临的核心挑战。通过综述靶向补体级联反应不同层级(启动层、放大层、效应层)的代表性生物药物,总结其作用机制、临床研究进展及适应证分布,从疗效与安全性角度对不同干预策略进行比较和分析,以期为靶向补体生物药物的研发和使用提供参考。
Abstract:The complement system plays a key role in maintaining immune homeostasis, and its abnormal activation is closely related to a variety of rare and common diseases. In recent years, the rapid development of biological drugs targeting the complement cascade has become an important research direction in immunotherapy. In general, complement-targeted therapy is moving from broad-spectrum blocking to precise intervention, which has significantly improved the clinical outcomes of various complement-mediated diseases. However, how to effectively control the risk of infection and the difference between individualized treatment and expanding indications is still the core challenge facing translational medicine. This paper systematically reviews the representative biological drugs targeting the complement cascade at different levels(initiation, amplification, and effector phases), summarizes the mechanism of action, clinical research progress and indication distribution, and compares and analyzes different intervention strategies from the perspective of efficacy and safety. The review is intended to provide a reference for the development and clinical application of complement-targeted biological drugs.
[1]AZOULAY E,ZUBER J,BOUSFIHA A A,et al.Complement system activation:bridging physiology,pathophysiology,and therapy[J].Intensive Care Med,2024,50(11):1791.
[2]WEST E E,WOODRUFF T, FREMEAUX-BACCHI V,et al.Complement in human disease:approved and up-and-coming therapeutics[J].Lancet,2024,403(10424):392.
[3]HO B H T,SPICER B A,DUNSTONE M A.Action of the terminal complement pathway on cell membranes[J].J Membr Biol,2025,258(4):269.
[4]GHOSH M,RANA S.The anaphylatoxin C5a:structure,function,signaling,physiology,disease,and therapeutics[J].Int Immunopharmacol,2023, 118:110081.
[5]HILLMEN P,SZER J,WEITZ I,et al.Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria[J].N Engl J Med,2021,384(11):1028.
[6]PITTOCK S J,BERTHELE A,FUJIHARA K,et al.Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder[J].N Engl J Med,2019,381(7):614.
[7]LEGENDRE C M,LICHT C,MUUS P,et al.Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome[J].N Engl J Med,2013,368(23):2169.
[8]DHILLON S.Sutimlimab:first approval[J].Drugs,2022,82(7):817.
[9]RÖTH A,BARCELLINI W,D'SA S,et al.Sutimlimab in cold agglutinin disease[J].N Engl J Med,2021,384(14):1323.
[10]RÖTH A,BERENTSEN S,BARCELLINI W,et al.Sutimlimab in patients with cold agglutinin disease:results of the randomized placebo-controlled phase 3 CADENZA trial[J].Blood,2022,140(9):980.
[11]ROMAN M,NOWICKI M.Targeting the roots of kidney disease:systematic review of the therapies targeting the complement system[J].Medicina,2025,61(7):1205.
[12]CASTELLI M,MICÒM C,GRASSI A,et al.Safety and efficacy of narsoplimab in pediatric and adult patients with transplantassociated thrombotic micro angiopathy:a real-world experience[J].Bone Marrow Transplant,2024,59(8):1161.
[13]SCHOETTLER M L,PUSARLA S K,NANGIA N,et al.Narsoplimab results in excellent survival in adults and children with hematopoietic cell transplant associated thrombotic microangiopathy(TA-TMA)[J].Am J Hematol,2025,100(11):2040.
[14]PEFFAULT DE LATOUR R,RÖTH A,KULASEKARARAJ A G,et al.Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria[J].N Engl J Med,2024,390(11):994.
[15]DE CASTRO C M,PATEL B J.Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria[J].Expert Opin Pharmacother,2024,25(18):2331.
[16]RISITANO A M,KULASEKARARAJ A G,SCHEINBERG P,et al.Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria:final 48-week results from the open-label,randomised,phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label,single-arm,phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors[J].Lancet Haematol,2025,12(6):e414.
[17]RISITANO A M,DE CASTRO C,HAN B,et al.Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies[J].Blood Adv,2025,9(8):1816.
[18]WONG E,NESTER C,CAVERO T,et al.Efficacy and safety of iptacopan in patients with C3 glomerulopathy[J].Kidney Int Rep,2023,8(12):2754.
[19]KAVANAGH D,BOMBACK A S,VIVARELLI M,et al.Oral iptacopan therapy in patients with C3 glomerulopathy:a randomised,double-blind,parallel group,multicentre,placebocontrolled,phase 3 study[J].Lancet,2025,406(10512):1587.
[20]ZHANG H,RIZK D V,PERKOVIC V,et al.Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy[J].Kidney Int,2024,105(1):189.
[21]PERKOVIC V,BARRATT J,ROVIN B,et al.Alternative complement pathway inhibition with iptacopan in IgA nephropathy[J].N Engl J Med,2025,392(6):531.
[22]RÖTH A,BARCELLINI W,ADEMOKUN C,et al.Iptacopan for immune thrombocytopenia and cold agglutinin disease:a globalphase 2 basket clinical trial[J].Am J Hematol,2026,101(2):242.
[23]LEE J W,GRIFFIN M,KIM J S,et al.Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis(ALPHA):a double-blind,randomised,phase 3 trial[J].Lancet Haematol,2023,10(12):e955.
[24]KULASEKARARAJ A,GRIFFIN M,PIATEK C,et al.Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH[J].Blood,2025,145(8):811.
[25]NESTER C, APPEL G B,BOMBACK A S, et al.Clinical outcomes of patients with C3G or IC-MPGN treated with the factor D inhibitor danicopan:final results from two phase 2 studies[J].Am J Nephrol,2023,53(10):687.
[26]HOY S M.Pegcetacoplan:first approval[J].Drugs,2021,81(12):1423.
[27]DE LATOUR R P,SZER J,WEITZ I C,et al.Pegcetacoplan versus eculizumab in patients with paro xysmal nocturnal haemoglobinuria(PEGASUS):48-week follow-up of a randomised,open-label,phase 3,active-comparator,controlled trial[J].Lancet Haematol,2022,9(9):e648.
[28]WONG R S M,NAVARRO-CABRERA J R,COMIA N S,et al.Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria[J].Blood Adv,2023,7(11):2468.
[29]PATRIQUIN C J,BOGDANOVIC A,GRIFFIN M,et al.Safety and efficacy of pegcetacoplan in adult patients with paroxysmal nocturnal hemoglobinuria over 48 weeks:307 open-label extension study[J].Adv Ther,2024,41(5):2050.
[30]GRIFFIN M,KELLY R,BRINDEL I,et al.Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria[J].Am J Hematol,2024,99(5):816.
[31] DIXON B P,GREENBAUM L A,HUANG L W,et al.Clinical safety and efficacy of pegcetacoplan in a phase 2 study of patients with C3 glomerulopathy and other complement-mediated glomerular diseases[J].Kidney Int Rep,2023,8(11):2284.
[32]BOMB ACK A S,DAINA E,REMUZZI G,et al.Efficacy and safety of pegcetacoplan in kidney transplant recipients with recurrent complement 3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis[J].Kidney Int Rep,2025,10(1):87.
[33]FAKHOURI F,BOMBACK A S,ARICETA G,et al.Trial of pegcetacoplan in C3 glomerulopathy and immune-complex MPGN[J].N Engl J Med,2025,393(22):2210.
[34]WYKOFF C C,HOLZ F G,CHIANG A,et al.Pegcetacoplan treatment for geographic atrophy in age-related macular degeneration over 36 months:data from OAKS,DERBY,and GALE[J].Am J Ophthalmol,2025,276:350.
[35]ROMAN E,FATTIZZO B,SHUM M,et al.Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia[J].Blood,2025,145(4):397.
[36]KULASEKARARAJ A,BRODSKY R,SCHREZENMEIER H,et al.Ravulizumab demonstrates long-term efficacy,safety and favorable patient survival in patients with paroxysmal nocturnalhemoglobinuria[J].Ann Hematol,2025,104(1):81.
[37]LEE J W,SICRE DE FONTBRUNE F,WONG LEE LEE L,et al.Ravulizumab(ALXN1210)vs eculizumab in adult patients with PNH naive to complement inhibitors:the 301 study[J].Blood,2019,133(6):530.
[38]PANSE J,HAN B,CERMAK J,et al.Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phaseⅢCOMMODORE 2 and 1 studies[J].Ann Hematol,2025,104(6):3199.
[39]WIJNSMA K L,DUINEVELD C,WETZELS J F M,et al.Eculizumab in atypical hemolytic uremic syndrome:strategies toward restrictive use[J].Pediatr Nephrol,2019,34(11):2261.
[40]DE SOUZA R M,CORREA B H M,MELO P H M,et al.The treatment of atypical hemolytic uremic syndrome with eculizumab in pediatric patients:a systematic review[J].Pediatr Nephrol,2023,38(1):61.
[41]RONDEAU E,SCULLY M,ARICETA G,et al.The long-acting C5inhibitor,ravulizumab,is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment[J].Kidney Int,2020,97(6):1287.
[42]ARICETA G,DIXON B P,KIM S H,et al.The long-acting C5inhibitor,ravulizumab,is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment[J].Kidney Int,2021,100(1):225.
[43]DIXON B P,KAVANAGH D,ARIS A D M,et al.Ravulizumab in atypical hemolytic uremic syndrome:an analysis of 2-year efficacy and safety outcomes in 2 phase 3 trials[J].Kidney Med,2024,6(8):100855.
[44]DHILLON S.Eculizumab:a review in generalized myasthenia gravis[J].Drugs,2018,78(3):367.
[45]MANTEGAZZA R,CAVALCANTE P.Eculizumab for the treatment of myasthenia gravis[J].Expert Opin Biol Ther,2020,20(9):991.
[46]MEISEL A,ANNANE D,VU T,et al.Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis:results from the phase 3 CHAMPION MG open-label extension[J].J Neurol,2023,270(8):3862.
[47]PITTOCK S J,BARNETT M,BENNETT J L,et al.Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder[J].Ann Neurol,2023,93(6):1053.
[48]MCNAMARA L A,TOPAZ N,WANG X, et al.High risk for invasive meningococcal disease among patients receiving eculizumab(Soliris)despite receipt of meningococcal vaccine[J].Am J Transplant,2017,17(9):2481.
[49]FATTIZZO B,VERSINO F,BARCELLINI W.Breakthrough hemoly sis in paroxysmal no cturnal hemo globinuria throughout clinical trials:from definition to clinical practice[J].Blood,2025,146(4):411.
[50]TER AVEST M,DUINEVELD C,BOUWMEESTER R N,et al.Prospective validation of initial eculizumab dosing in adults with atypical hemolytic uremic syndrome[J].Nephrol Dial Transplant,2025,40(3):598.
[51]AFSHAR-KHARGHAN V.Long-term outcome and management of complement-mediated thrombotic microangiopathy/aHUS[J].Hematology,2025(1):147.
[52]SHI J J,OZCAN Y M,SANTOS C I A,et al.Current landscape of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitors and regulators[J].Ther Adv Hematol,2024,15:20406207241307500.
[53]GRIFFIN M,GANDHI S,KELLY R J,et al.Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab:a phaseⅣ,single-arm clinical trial[J].Haematologica,2025,110(4):967.
[54]KULASEKARARAJ A G,HILL A,ROTTINGHAUS S T,et al.Ravulizumab(ALXN1210)vs eculizumab in C5-inhibitorexperienced adult patients with PNH:the 302 study[J].Blood,2019,133(6):540.
[55]RÖTH A,NISHIMURA J I,NAGY Z,et al.The complement C5inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria[J].Blood,2020,135(12):912.
[56]SCHEINBERG P,CLÉD V,KIM J S, et al.Phase 3 randomized COMMODORE 1 trial:crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria[J].Am J Hematol,2024,99(9):1757.
[57]LIU H,XIA L H,WENG J Y,et al.Efficacy and safety of the C5inhibitor crovalimab in complement inhibitor-naive patients with PNH(COMMODORE 3):a multicenter,Phase 3,single-arm study[J].Am J Hematol,2023,98(9):1407.
[58]DHILLON S.Crovalimab:first approval[J].Drugs,2024,84(6):707.
[59]KHANANI A M,PATEL S S, STAURENGHI G,et al.Efficacy and safety of avacincaptad pegol in patients with geographic atrophy(GATHER2):12-month results from a randomised,double-masked,phase 3 trial[J].Lancet,2023,402(10411):1449.
[60]KHANANI A M,DANZIG C J,HEIER J S, et al.Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration two-year efficacy and safety results from the GATHER2 phase 3 trial[J].Ophthalmology,2026,133(4):451.
[61]OZEN A,CHONGSRISAWAT V,SEFER A P,et al.Evaluating theefficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement,angiopathic thrombosis,and protein-losing enteropathy disease:an open-label phase 2 and 3study[J].Lancet,2024,403(10427):645.
[62]BAUER M,WEYLAND A,MARX G,et al.Efficacy and safety of vilobelimab(IFX-1),a novel monoclonal anti-C5a antibody,in patients with early severe sepsis or septic shock:a randomized,placebo-controlled,double-blind,multicenter,phaseⅡa trial(SCIENS study)[J].Crit Care Explor,2021,3(11):e0577.
[63]VLAAR A P J,DE BRUIN S,BUSCH M,et al.Anti-C5a antibody IFX-1(vilobelimab)treatment versus best supportive care for patients with severe COVID-19(PANAMO):an exploratory,openlabel,phase 2 randomised controlled trial[J].Lancet Rheumatol,2020,2(12):e764.
[64]VLAAR A P J,WITZENRATH M,VAN PAASSEN P,et al.AntiC5a antibody(vilobelimab)therapy for critically ill,invasively mechanically ventilated patients with COVID-19(PANAMO):a multicentre,double-blind,randomised,placebo-controlled,phase 3trial[J].Lancet Respir Med,2022,10(12):1137.
[65]LIM E H T,VLAAR A P J,DE BRUIN S,et al.Pharmacokinetic analysis of vilobelimab,anaphylatoxin C5a and antidrug antibodies in PANAMO:a phase 3 study in critically ill,invasivelymechanically ventilated COVID-19 patients[J].Intensive Care Med Exp,2023,11(1):37.
[66]NADIG N,BHIMRAJ A,CAWCUTT K,et al.2025 clinical practice guideline update by the Infectious Diseases Society of America on the treatment and management of COVID-19:vilobelimab[J].Clin Infect Dis,2026,81(S3):i13.
[67]CORTAZAR F B,NILES J L,JAYNE D R W,et al.Renal recovery for patients with ANCA-associated vasculitis and low eGFR in the ADVOCATE trial of avacopan[J].Kidney Int Rep,2023,8(4):860.
[68]MORI K,SHIRAI T,MUTOH T,et al.Drug-induced liver injury related to avacopan therapy[J].Rheumatology(Oxford),2025,64(5):2533.
基本信息:
DOI:10.19577/j.1007-4406.2026.09.004
中图分类号:R97
引用信息:
[1]陈靖雯,南艳阳,鞠佃文.靶向补体生物药物的研究进展及其临床应用[J].中国临床药学杂志,2026,35(09):792-801.DOI:10.19577/j.1007-4406.2026.09.004.
基金信息:
国家重点研发计划(编号2023YFC3404000); 国家自然科学基金(编号82371781)
2026-09-25
2026-09-25